Literature DB >> 22331912

High-grade serous ovarian cancer arises from fallopian tube in a mouse model.

Jaeyeon Kim1, Donna M Coffey, Chad J Creighton, Zhifeng Yu, Shannon M Hawkins, Martin M Matzuk.   

Abstract

Although ovarian cancer is the most lethal gynecologic malignancy in women, little is known about how the cancer initiates and metastasizes. In the last decade, new evidence has challenged the dogma that the ovary is the main source of this cancer. The fallopian tube has been proposed instead as the primary origin of high-grade serous ovarian cancer, the subtype causing 70% of ovarian cancer deaths. By conditionally deleting Dicer, an essential gene for microRNA synthesis, and Pten, a key negative regulator of the PI3K pathway, we show that high-grade serous carcinomas arise from the fallopian tube in mice. In these Dicer-Pten double-knockout mice, primary fallopian tube tumors spread to engulf the ovary and then aggressively metastasize throughout the abdominal cavity, causing ascites and killing 100% of the mice by 13 mo. Besides the clinical resemblance to human serous cancers, these fallopian tube cancers highly express genes that are known to be up-regulated in human serous ovarian cancers, also demonstrating molecular similarities. Although ovariectomized mice continue to develop high-grade serous cancers, removal of the fallopian tube at an early age prevents cancer formation--confirming the fallopian tube origin of the cancer. Intriguingly, the primary carcinomas are first observed in the stroma of the fallopian tube, suggesting that these epithelial cancers have a mesenchymal origin. Thus, this mouse model demonstrates a paradigm for the origin and initiation of high-grade serous ovarian carcinomas, the most common and deadliest ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22331912      PMCID: PMC3309733          DOI: 10.1073/pnas.1117135109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

Authors:  David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

Review 2.  The management of recurrent ovarian cancer.

Authors:  Ronald M Bukowski; Robert F Ozols; Maurie Markman
Journal:  Semin Oncol       Date:  2007-04       Impact factor: 4.929

Review 3.  Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses.

Authors:  Jean S Fleming; Clare R Beaugié; Izhak Haviv; Georgia Chenevix-Trench; Olivia L Tan
Journal:  Mol Cell Endocrinol       Date:  2005-11-16       Impact factor: 4.102

Review 4.  The distal fallopian tube: a new model for pelvic serous carcinogenesis.

Authors:  Christopher P Crum; Ronny Drapkin; Alexander Miron; Tan A Ince; Michael Muto; David W Kindelberger; Yonghee Lee
Journal:  Curr Opin Obstet Gynecol       Date:  2007-02       Impact factor: 1.927

Review 5.  Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.

Authors:  Christopher P Crum; Ronny Drapkin; David Kindelberger; Fabiola Medeiros; Alexander Miron; Yonghee Lee
Journal:  Clin Med Res       Date:  2007-03

6.  Dicer, Drosha, and outcomes in patients with ovarian cancer.

Authors:  William M Merritt; Yvonne G Lin; Liz Y Han; Aparna A Kamat; Whitney A Spannuth; Rosemarie Schmandt; Diana Urbauer; Len A Pennacchio; Jan-Fang Cheng; Alpa M Nick; Michael T Deavers; Alexandra Mourad-Zeidan; Hua Wang; Peter Mueller; Marc E Lenburg; Joe W Gray; Samuel Mok; Michael J Birrer; Gabriel Lopez-Berestein; Robert L Coleman; Menashe Bar-Eli; Anil K Sood
Journal:  N Engl J Med       Date:  2008-12-18       Impact factor: 91.245

7.  Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study.

Authors:  William H Parker; Michael S Broder; Eunice Chang; Diane Feskanich; Cindy Farquhar; Zhimae Liu; Donna Shoupe; Jonathan S Berek; Susan Hankinson; JoAnn E Manson
Journal:  Obstet Gynecol       Date:  2009-05       Impact factor: 7.661

8.  Deletion of Dicer in somatic cells of the female reproductive tract causes sterility.

Authors:  Ankur K Nagaraja; Claudia Andreu-Vieyra; Heather L Franco; Lang Ma; Ruihong Chen; Derek Y Han; Huifeng Zhu; Julio E Agno; Preethi H Gunaratne; Francesco J DeMayo; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2008-08-07

9.  A mesenchymal perspective of Müllerian duct differentiation and regression in Amhr2-lacZ mice.

Authors:  Nelson A Arango; Akio Kobayashi; Ying Wang; Soazik P Jamin; Hu-Hui Lee; Grant D Orvis; Richard R Behringer
Journal:  Mol Reprod Dev       Date:  2008-07       Impact factor: 2.609

10.  Characterization of clonogenic stromal cells isolated from human endometrium.

Authors:  R Dimitrov; T Timeva; D Kyurkchiev; M Stamenova; A Shterev; P Kostova; V Zlatkov; I Kehayov; S Kyurkchiev
Journal:  Reproduction       Date:  2008-04       Impact factor: 3.906

View more
  152 in total

Review 1.  It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.

Authors:  Ruth Perets; Ronny Drapkin
Journal:  Cancer Res       Date:  2015-12-15       Impact factor: 12.701

2.  Targeting progesterone signaling prevents metastatic ovarian cancer.

Authors:  Olga Kim; Eun Young Park; Sun Young Kwon; Sojin Shin; Robert E Emerson; Yong-Hyun Shin; Francesco J DeMayo; John P Lydon; Donna M Coffey; Shannon M Hawkins; Lawrence A Quilliam; Dong-Joo Cheon; Facundo M Fernández; Kenneth P Nephew; Adam R Karpf; Martin Widschwendter; Anil K Sood; Robert C Bast; Andrew K Godwin; Kathy D Miller; Chi-Heum Cho; Jaeyeon Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-01       Impact factor: 11.205

3.  Screening for ovarian cancer: imaging challenges and opportunities for improvement.

Authors:  K B Mathieu; D G Bedi; S L Thrower; A Qayyum; R C Bast
Journal:  Ultrasound Obstet Gynecol       Date:  2018-03       Impact factor: 7.299

4.  Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.

Authors:  Ruth Perets; Gregory A Wyant; Katherine W Muto; Jonathan G Bijron; Barish B Poole; Kenneth T Chin; Jin Yun H Chen; Anders W Ohman; Corey D Stepule; Soongu Kwak; Alison M Karst; Michelle S Hirsch; Sunita R Setlur; Christopher P Crum; Daniela M Dinulescu; Ronny Drapkin
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

5.  Preventing ovarian cancer by salpingectomy.

Authors:  W D Foulkes
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

Review 6.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

Review 7.  The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.

Authors:  Xiyin Wang; Mircea Ivan; Shannon M Hawkins
Journal:  Gynecol Oncol       Date:  2017-08-31       Impact factor: 5.482

Review 8.  Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.

Authors:  Bayley A Jones; Sooryanarayana Varambally; Rebecca C Arend
Journal:  Mol Cancer Ther       Date:  2018-03       Impact factor: 6.261

9.  In Utero Exposure to Benzo[a]pyrene Induces Ovarian Mutations at Doses That Deplete Ovarian Follicles in Mice.

Authors:  Ulrike Luderer; Matthew J Meier; Gregory W Lawson; Marc A Beal; Carole L Yauk; Francesco Marchetti
Journal:  Environ Mol Mutagen       Date:  2018-12-21       Impact factor: 3.216

10.  Isomer-specific LC/MS and LC/MS/MS profiling of the mouse serum N-glycome revealing a number of novel sialylated N-glycans.

Authors:  Serenus Hua; Ha Neul Jeong; Lauren M Dimapasoc; Inae Kang; Chanyoung Han; Jong-Soon Choi; Carlito B Lebrilla; Hyun Joo An
Journal:  Anal Chem       Date:  2013-04-18       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.